Comparative Pharmacology
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE versus XERMELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPERAMIDE HYDROCHLORIDE versus XERMELO.
LOPERAMIDE HYDROCHLORIDE vs XERMELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide binds to µ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing intestinal transit time. It also inhibits calcium-calmodulin-dependent pathways, decreasing electrolyte and water secretion, and enhances anal sphincter tone.
Telotristat ethyl is a prodrug that is hydrolyzed to the active metabolite telotristat, an inhibitor of tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in the peripheral conversion of tryptophan to serotonin. By inhibiting TPH, telotristat reduces serotonin production in the gut, thereby decreasing gastrointestinal motility and secretion, and reducing diarrhea associated with carcinoid syndrome.
4 mg orally initially, followed by 2 mg after each unformed stool; maximum 16 mg per day. For chronic diarrhea, 4 mg orally once, then 2 mg after each unformed stool until diarrhea controlled; typical maintenance 4-8 mg daily in divided doses. Traveler's diarrhea: 4 mg initially, then 2 mg after each loose stool; maximum 8 mg per day for up to 2 days.
250 mg orally three times daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 9-14 hours (mean 10.8 hours) in adults; may be prolonged in hepatic impairment.
Terminal elimination half-life is approximately 6-10 hours in patients with carcinoid syndrome, supporting twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged to up to 19 hours.
Primarily fecal (30-40% as unchanged drug, 50-60% as metabolites); renal excretion accounts for <5% of unchanged drug and ~10% of metabolites.
Primarily excreted via feces (approximately 82% of absorbed dose) with a minor renal component (approximately 12% of absorbed dose as unchanged drug and metabolites).
Category A/B
Category C
Antidiarrheal
Antidiarrheal